Servier’s Tibsovo Opens The Door To A New Era I...

Niemann-Pick disease type C (NPC) is a rare genetic disorder caused by mutations in cholesterol trafficking proteins. There are two main types, with Type C1 being the most prevalent, accounting for around 95% of cases. While specific epidemiological data on NPC is limited, estimates suggest a prevalence of approxim...

Bone sarcoma is a rare and aggressive form of cancer that develops in bone tissue. The likelihood of a person being diagnosed with primary bone sarcoma and their recovery prospects depend on various unique factors. In 2023, it is expected that 4,000 individuals across all age groups in the United States will receiv...

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The...

The evolution of technology has been a driving force behind the remarkable growth of the Insulin Pens market. Insulin Pens, from their inception as relatively basic delivery devices, have undergone a substantial transformation, becoming highly advanced and user-friendly tools. In the early stages, these pens requir...

Ardelyx has struck gold on its third attempt with Xphozah (tenapanor), the chronic kidney disease medication. Following two prior rejections, the FDA has granted its long-awaited approval. Xphozah, an innovative phosphate absorption inhibitor, is now officially sanctioned for the management of serum phosphate level...

Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III resul...